Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases.
SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-androgen targeting therapies. This article describes the preclinical rationale for the use of combination dasatinib and docetaxel therapy in mCRPC, and highlights the results of a phase I-II trial in which 46 patients with mCRPC, treated with a regimen of dasatinib and docetaxel, demonstrated improvements in bone scans, high rates of soft tissue responses, and modulation of markers of bone turnover. This brief report discusses in detail follow-up data on two patients who remain alive after >2.5 years on dasatinib single-agent therapy after discontinuing docetaxel treatment.
Written by:
Araujo JC, Trudel GC, Paliwal P. Are you the author?
Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reference: Cancer Manag Res. 2013;6:25-30.
doi: 10.2147/CMAR.S41667
PubMed Abstract
PMID: 23516140
